Explanatory note
(This note is not part of the Order)
This Order prohibits, subject to exceptions, the retail sale, and the supply in circumstances corresponding to retail sale, of medicinal products that consist of or contain a list of gonadotrophin-releasing hormone (“GnRH”) analogues (article 4). It is the fourth such Order – and is made in effectively the same terms as the temporary Order which preceded it, the Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (Extension) (No. 2) Order 2024 (S.I. 2024/1110), which expires immediately before this Order comes into force.
Supplies of GnRH analogues as part of authorised clinical trials are excluded from the prohibition (article 3), as are orders for GnRH analogues in pursuance of NHS prescriptions or directions (article 5).
In the case of sales or supplies of GnRH analogues in pursuance of private prescriptions or directions, different conditions apply depending on the age of the patients. If the patient is 18 or over, GnRH analogues can continue to be sold or supplied for any purposes, but if the order for the GnRH analogue is in one of the standard formats for a prescription (as most have to be because of regulation 214(1) of the Human Medicines Regulations 2012 (S.I. 2012/1916)), there are prescription formalities in some cases, and age and identity checks in others. Age and identity checks will not be necessary where a patient’s age is included in the prescription and an approved UK prescriber annotates the prescription with ‘SLS’ (article 6).
If the private prescription or direction is for a patient who is under 18, if the order is in one of the standard formats for a prescription there are again prescription formalities in some cases, and age and identity checks in others. In addition, only a limited range of authorised prescribers – a list of approved UK prescribers – will be able to have dispensed new prescriptions or directions that are issued after the start of the applicable restrictions. This list of approved prescribers does not include prescribers who are not United Kingdom registered.
Also, for patients under 18 the prescription or direction must be for a purpose other than treatment for the purpose of puberty suppression in respect of either or a combination of gender dysphoria and gender incongruence, subject to an exception. The exception is that a patient under 18 who is in this category but who started a course of treatment with a GnRH analogue before 3rd June 2024, as the Order applies in England and Wales and Scotland, or before 27th August 2024, as the Order applies in Northern Ireland, may continue to have GnRH analogues sold or supplied to or for them (articles 7 and 8).
Provision is also made for reviews on a four-year cycle, although the first review needs to be completed, with the publication of a report, by 1st October 2027 (article 9).
An impact assessment has been produced for this instrument and is available from the Department of Health and Social Care, 39 Victoria Street, London SW1H 0EU. A copy of it is also published alongside this instrument on www.legislation.gov.uk.